Cargando…
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
BACKGROUND: Malignant pleural mesothelioma is an aggressive tumor that has a poor prognosis and is resistant to unimodal approaches. Multimodal treatment has provided encouraging results. METHODS: Phase II, open-label study of the combination of chemotherapy (pemetrexed 500 mg/m(2)+cisplatin 75 mg/m...
Autores principales: | Federico, Rea, Adolfo, Favaretto, Giuseppe, Marulli, Lorenzo, Spaggiari, Martino, DePas Tommaso, Anna, Ceribelli, Adriano, Paccagnella, Gino, Crivellari, Francesca, Russo, Matteo, Ceccarelli, Gbenga, Kazeem, Paolo, Marchi, Francesco, Facciolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722081/ https://www.ncbi.nlm.nih.gov/pubmed/23324131 http://dx.doi.org/10.1186/1471-2407-13-22 |
Ejemplares similares
-
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
por: Ceresoli, G L, et al.
Publicado: (2008) -
Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008) -
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013) -
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016) -
Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)